In conclusion, these findings suggest that NP-NAR may be a promising candidate for the treatment of obesity-associated MASLD, offering new insight into the mechanisms underlying NAR’s efficacy against MASLD. Here, CPSF4 is linked to obesity due to melanocortin 4 receptor deficiency.